disomet 200 mg depottabletti
orion oyj - disopyramidi phosphas - depottabletti - 200 mg - disopyramidi
viscoat liuos silmänsisäistä applisointia varten
s.a. alcon couvreur n.v. - natrii hyaluronas,natrii chondroitini sulfas - liuos silmänsisäistä applisointia varten - hyaluronihappo, yhdistelmävalmisteet
betnovat 1 mg/g voide
glaxosmithkline oy - betamethasone valerate - voide - 1 mg/g - beetametasoni
betnovat 1 mg/g emulsiovoide
glaxosmithkline oy - betamethasoni valeras - emulsiovoide - 1 mg/g - beetametasoni
betnovat 1 mg/ml liuos iholle
glaxosmithkline oy - betamethasone valerate - liuos iholle - 1 mg/ml - beetametasoni
dermovat 0.5 mg/g emulsiovoide
glaxosmithkline oy - clobetasol propionate - emulsiovoide - 0.5 mg/g - klobetasoli
dermovat 0.5 mg/g voide
glaxosmithkline oy - clobetasol propionate - voide - 0.5 mg/g - klobetasoli
letrozol orion 2.5 mg tabletti, kalvopäällysteinen
orion corporation - letrozolum - tabletti, kalvopäällysteinen - 2.5 mg - letrotsoli
letrozol orion 2.5 mg tabletti, kalvopäällysteinen
orion corporation - letrozolum - tabletti, kalvopäällysteinen - 2.5 mg - letrotsoli
thyrogen
sanofi b.v. - tirotropiini alfa - kilpirauhasen vajaatoiminta - anterior aivolisäkkeen etulohkon hormonit ja analogit, aivolisäkkeen ja hypotalamuksen hormonit sekä analogit - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.